Genetic variants related to successful migraine prophylaxis with verapamil.

ABSTRACT:

Background

Currently, there is no biologically based rationale for drug selection in migraine prophylactic treatment.

Methods

To investigate the genetic variation underlying treatment response to verapamil prophylaxis, we selected 225 patients from a longitudinally established, deeply phenotyped migraine database (N = 5983), and collected uninterrupted quantitated verapamil treatment response data and DNA for these 225 cases. We recorded the number of headache days in the four weeks preceding treatment with verapamil and for four weeks, following completion of a treatment period with verapamil lasting at least five weeks. Whole-exome sequencing (WES) was applied to a discovery cohort consisting of 21 definitive responders and 14 definitive non-responders, and the identified

SUBMITTER: Cutrer FM 

PROVIDER: S-EPMC8222836 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature